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Abstract
Background Seizures are an important comorbidity in Alzheimer’s disease (AD). Conflicting results regarding clinical 
parameters associated with seizures in AD were previously reported. Data on seizure recurrence risk, a crucial parameter 
for treatment decisions, are lacking.
Methods National Alzheimer’s Coordinating Center data were analyzed. Seizure prevalence in AD and an association with 
disease duration were investigated. Associations of seizures with age of AD onset and with cognitive and functional perfor-
mance, and seizure recurrence risk were studied.
Results 20,745 individuals were investigated. In AD dementia, seizure recurrence risk was 70.4% within 7.5 months. Sei-
zure history was associated with an earlier age of onset of cognitive symptoms (seizures vs. no seizures: 64.7 vs. 70.4 years; 
p < 0.0001) and worse cognitive and functional performance (mean MMSE score: 16.6 vs. 19.6; mean CDR-sum of boxes 
score: 9.3 vs. 6.8; p < 0.0001; adjusted for disease duration and age). Seizure prevalence increased with duration of AD 
dementia (standardized OR = 1.55, 95% CI = 1.39–1.73, p < 0.0001), rising from 1.51% at 4.8 years to 5.43% at 11 years dis-
ease duration. Seizures were more frequent in AD dementia compared to normal controls (active seizures: 1.51% vs. 0.35%, 
p < 0.0001, OR = 4.34, 95% CI = 3.01–6.27; seizure history: 3.14% vs. 1.57%, p < 0.0001, OR = 2.03, 95% CI = 1.67–2.46).
Conclusion Seizures in AD dementia feature an exceptionally high recurrence risk and are associated with a poor course 
of cognitive symptoms. AD patients are at an increased risk for seizures, particularly in later disease stages. Our findings 
emphasize a need for seizure history assessment in AD, inform individual therapeutic decisions and underline the necessity 
of systematic treatment studies of AD-associated epilepsy.
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Introduction
In Alzheimer’s disease (AD), cognitive symptoms represent 
the intrinsic clinical manifestation, but also non-cognitive 
symptoms affect individuals with AD [1, 2]. As the preva-
lence of AD is estimated to further increase in the future, there 
will be a mounting burden for patients and their families as 
well as for society [3]. Therefore, non-cognitive symptoms 
associated with AD will gain importance and will be needed 
to be addressed. Such a symptom are seizures. An associa-
tion between Alzheimer’s disease and seizures was reported in 
several studies with figures for seizure prevalence in AD from 
0.5% up to 64% [4, 5]. In autosomal dominant AD, that can 
be considered as a model disease of the sporadic form without 
age-associated comorbidities, there is an increased likelihood 
for the occurrence of seizures [2, 6], even very early in the dis-
ease course when cognitive impairment is absent [7]. A causal 
connection between AD and seizure pathophysiology is sug-
gested by a number of mouse models for AD, which frequently 
show epileptiform activity on EEG and overt seizures [8]. The 
National Alzheimer’s Coordinating Center (NACC), estab-
lished to facilitate collaborative research, runs a database that 
is unique for its size [9]. The clinical information entered fol-
lows the standardized manner of the Uniform Data Set (UDS) 
[10, 11]. Open questions with respect to the recurrence risk 
of seizures in AD including potential consecutive treatment 
implications, regarding the connection between seizures and 
disease course as well as regarding the association of seizures 
with disease duration subsist. Using the NACC dataset, we 
aimed to investigate the clinical course of seizures and possible 
implications for antiepileptic treatment decisions.
Methods
Participants
The NACC database containing data from 34 past and pre-
sent Alzheimer’s disease centers (ADCs) in the USA was 
used for this study. Data of the UDS [10] from visits con-
ducted between September 2005 and February 2016 were ana-
lyzed. NACC data has been described in detail before [8–12]. 
Research utilizing the NACC database was approved by the 
Institutional Review Board of the Ludwig-Maximilians Uni-
versity, Munich, Germany. Informed consent from individuals 
that are part of the NACC datasets was obtained at the respec-
tive ADCs.
Assessment of seizures and AD stage
In the UDS [10], occurrence of seizures is assessed by infor-
mation obtained from the study participant and a manda-
tory co-participant interview, from medical records and from 
observation. Four options are at choice: “Absent” (seizures 
are not indicated), “Recent/Active” (seizures happened 
within the last year or still require active management and 
are consistent with information obtained from the subject 
and co-participant interview), “Remote/Inactive” (seizures 
existed or occurred in the past—more than one year ago—
but were resolved or there is no treatment currently under 
way), or “Unknown” (insufficient information available from 
the subject and co-participant interview). From now on, if 
“Seizures” are stated “Recent/Active”, they are referred to 
as active seizures.
The cognitive status is categorized in the NACC-UDS 
according to the four mutually exclusive options normal 
cognition, MCI (mild cognitive impairment), impaired-not-
MCI (subjects who are objectively cognitively impaired 
but who do not meet the criteria for MCI considering the 
subject’s presentation, test results, symptoms, and clini-
cal evaluation) or dementia. In subjects with any cognitive 
impairment (dementia, MCI, or impaired-not-MCI), the 
presumptive etiologic diagnosis is stated by the respective 
trained rater. For an etiologic diagnosis of AD, either the 
NINCDS/ADRDA (National Institute of Neurological and 
Communicative Disorders and Stroke/Alzheimer’s Disease 
and Related Disorders Association) criteria [13] or the NIA-
AA (National Institute on Aging-Alzheimer’s Association) 
criteria for AD dementia [14] were applied.
For analysis of seizure prevalence at baseline visits, we 
defined five groups. Presymptomatic AD (normal cogni-
tion at baseline), AD impaired-not-MCI, AD MCI, AD 
dementia, and controls (Fig. 1). The cognitive status of a 
participant is determined at every NACC study visit with the 
options “normal cognition”, “impaired-not-MCI”, “MCI” 
and “dementia” at choice. If a participant was attested 
Fig. 1  Flow chart depicting the study population at baseline and sepa-
ration into subgroups. For pre-symptomatic Alzheimer’s disease, a 
normal cognitive status at baseline and a diagnosis of Alzheimer’s 
disease dementia at follow-up was required. For impaired-not-MCI 
due to Alzheimer’s disease and MCI due to Alzheimer’s disease, both 
a presumptive etiologic diagnosis of Alzheimer’s disease at baseline 
and a diagnosis of Alzheimer’s disease dementia at follow-up were 
required. Groups that were included in analyses are shown in bold. 
MCI mild cognitive impairment
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“normal cognition” based on the overall impression taking 
all assessments of the respective visit into account by the 
respective trained clinical raters at all study visits (at base-
line and follow-ups), she or he was allocated to the control 
group for this study. To increase the accuracy of the etiologic 
diagnosis of AD in cognitively impaired participants and to 
define the group with presymptomatic AD, a diagnosis of 
AD dementia at a subsequent visit of the respective partici-
pant was stipulated for the classification into a pre-dementia 
stage of AD.
Clinical course of seizures in AD dementia
In individuals with AD dementia at baseline, the preva-
lence of active seizures and disease duration at the baseline 
visit and 8 subsequent follow-up visits were calculated. To 
determine disease duration, each individual’s age of onset 
of cognitive decline was subtracted from his or her age at 
the respective visit. The age of onset of cognitive decline is 
assessed for each participant in a standardized manner as 
part of UDS.
For assessment of seizure recurrence risk in AD dementia 
we calculated the proportion of patients with active seizures 
at the first follow-up visit of those who already suffered from 
active seizures at baseline and presented for follow-up. Cog-
nitive and functional performance at baseline was compared 
between AD dementia patients with and without seizures.
Statistical analyses
Clinical and demographic features of the study popula-
tion at baseline were analyzed and compared between sub-
groups using Fisher’s exact test, Kruskal–Wallis test and 
Mann–Whitney U test (Tables 1 and 2). Each AD group 
(presymptomatic, impaired-not-MCI, MCI, dementia) was 
compared to controls regarding the prevalence of active sei-
zures and a history of seizures at baseline using Fisher’s 
exact test (Fig. 4). In cases of statistically significant group 
differences, odds ratios (OR) and 95% confidence intervals 
(CI) were calculated. Regarding a potential association 
between seizure prevalence and disease duration, different 
transformations of the disease duration were considered 
to improve the fit between the two variables. The best fit 
was provided by a logistic regression with disease duration 
square-transformed and standardized as explanatory variable 
(Fig. 3). For analysis of respective baseline cognitive and 
functional performance we compared AD dementia patients 
with and without seizures with respect to mean mini men-
tal state examination (MMSE) [15] and clinical dementia 
rating-sum of boxes (CDR-SB) [16] scores in a generalized 
linear model with disease duration and age as co-variables. 
To assess the impact of seizures on the cognitive and func-
tional trajectory as measured by CDR-SB, a general linear 
model with history of seizures (yes vs. no) and disease dura-
tion as independent variables and CDR-SB as dependent 
variable including a history of seizures*disease duration 
interaction was used. p values below 0.05 were considered 
statistically significant. All tests were performed two-sided. 
The Statistical Package for the Social Sciences (IBM SPSS 




We identified a total of 20,745 individuals with compre-
hensive clinical data at baseline (March 2016 NACC data 
freeze). Of these, 10,527 were diagnosed with AD and 
10,218 were cognitively asymptomatic controls. 498 of the 
individuals with AD were classified, as described in the 
methods section, as pre-symptomatic, 43 as impaired-not-
MCI, 859 as MCI, and 9127 as demented (Fig. 1). Baseline 
characteristics of these subpopulations are shown in Table 1.
Seizure recurrence risk
At baseline 138 AD dementia patients with active seizures 
were identified. After a mean of 7.46 months, 60 of them 
presented for follow-up (corresponding to a dropout rate of 
56.5%), and for 54 of these 60 data for seizures were availa-
ble. Out of these 54 individuals, 38 still suffered from active 
seizures. These figures result in a risk for seizure recurrence 
of 70.4% within 7.46 months.
Seizures, cognitive performance and age of AD 
onset
With respect to cognition and function, AD dementia 
patients with a history of seizures performed worse in 
MMSE as well as in CDR-SB compared to those with-
out (mean MMSE score: 16.6 vs. 19.6, p < 0.001; mean 
CDR-SB score: 9.3 vs. 6.8, p < 0.001) after adjustment 
for disease duration and age (Table 2). There was a highly 
significant effect of a positive history of seizures on the 
CDR-SB towards abnormal over disease duration (history 
of seizures*disease duration: F = 18.66; p < 0.001) (Fig. 2). 
The age of onset of cognitive symptoms was earlier in AD 
dementia patients with seizures compared to those without 
(64.7 vs. 70.4 years, p < 0.001).
Disease duration and seizure prevalence
The effect of disease duration on seizure prevalence 
was highly significant in patients with AD dementia 
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(standardized OR = 1.55, 95% CI = 1.39–1.73, p < 0.001). 
The frequency of active seizures amounted to 1.51% after 
4.8 years of AD dementia duration and increased to 5.43% 
at 11.0 years of disease course. On average, prevalence of 
active seizures in AD dementia rose by 0.64% per year of 
disease duration (Fig. 3).
Seizure prevalence
Active seizures were significantly more prevalent in 
patients with AD dementia than in controls (1.51% vs. 
0.35%, OR = 4.34, 95% CI = 3.01–6.27, p < 0.001). Further, 
AD dementia patients revealed a history of seizures at a 
higher frequency compared to controls (3.14% vs. 1.57%, 
OR = 2.03, 95% CI = 1.67–2.46, p < 0.001) (Fig. 4).
No differences in the prevalence of active seizures were 
found in individuals with pre-symptomatic AD (0.4%, 
Table 2  Comparison of clinical and demographic baseline characteristic between Alzheimer’s disease dementia patients with and without sei-
zures
AD Alzheimer’s disease, SD standard deviation, MMSE mini mental state examination, CDR-SB clinical dementia rating-sum of boxes
1 p Value is derived from Mann–Whitney U test
2 p Value is derived from Fisher’s exact test
3 After adjustment for age and disease duration in a generalized linear model
AD dementia patients with 
seizures (n = 287)
AD dementia patients without 
seizures (n = 8840)
Total (n = 9127) P value
Mean age ± SD, years 71.1 ± 10.9 75.2 ± 9.8 75.1 ± 9.9  < 0.0011
Female: male, No 154: 133 4986: 3854 5140: 3987 0.362
Mean age of onset ± SD, years 64.7 ± 11.2 70.4 ± 9.9 70.2 ± 10.0  < 0.0011
Mean disease duration ± SD, years 6.3 ± 4.1 4.8 ± 3.3 4.8 ± 3.4  < 0.0011
Mean MMSE score ± SD 16.6 ± 8.6 19.6 ± 6.6 19.5 ± 6.7  < 0.0013
Mean CDR-SB score ± SD 9.3 ± 5.8 6.8 ± 4.3 6.8 ± 4.4  < 0.0013
Disease duration (years)














Fig. 2  Grouped scatter plot depicting CDR-SB as a function of the 
presence of a history of seizures and disease duration. There was a 
highly significant effect of the presence of a history of seizures on 
CDR-SB towards abnormal over disease duration. Middle lines rep-
resent the linear fits of the data, upper and lower lines represent 95% 
confidence intervals. CDR-SB clinical dementia rating-sum of boxes
Table 1  Study subpopulations, baseline characteristics and prevalence of seizures
AD Alzheimer’s Disease, MCI mild cognitive impairment, SD standard deviation, MMSE Mini mental state examination, CDR-SB clinical demen-
tia rating-sum of boxes
1 Fisher’s exact test comparing the groups AD dementia and controls. No statistically significant differences were found while comparing each 
other AD group to controls
2 Kruskal–Wallis test comparing the groups pre-symptomatic AD, AD impaired-not-MCI, AD MCI, AD dementia and controls
3 Pearson’s Chi square test comparing the groups pre-symptomatic AD, AD impaired-not-MCI, AD MCI, AD dementia and controls
Pre-symptomatic 
AD (n = 498)
AD impaired-
not-MCI (n = 43)
AD MCI (n = 859) AD dementia 
(n = 9127)
Controls (n = 10,218) p value
Active seizures, No. (%) 2 (0.4) 1 (2.33) 1 (0.12) 138 (1.51) 36 (0.35)  < 0.0011
History of seizures, No. (%) 9 (1.8) 1 (2.33) 11 (1.28) 287 (3.14) 161 (1.57)  < 0.0011
Mean age ± SD, years 79.8 ± 7.7 74.9 ± 9.0 75.1 ± 8.3 75.1 ± 9.9 69.8 ± 10.9  < 0.0012
Female: male, No. 325: 173 23: 20 427: 432 5140: 3987 6730: 3488  < 0.0013
Mean MMSE score ± SD 28.2 ± 1.8 27.2 ± 2.6 26.1 ± 2.7 19.5 ± 6.7 28.9 ± 1.4  < 0.0012
Mean CDR-SB score ± SD 0.3 ± 0.6 1.7 ± 1.3 1.9 ± 1.2 6.8 ± 4.4 0.1 ± 0.3  < 0.0012
Mean global CDR score ± SD 0.10 ± 0.20 0.49 ± 0.17 0.51 ± 0.11 1.19 ± 0.74 0.04 ± 0.14  < 0.0012
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p = 0.70), AD impaired-not-MCI (2.33%, p = 0.14) and AD 
MCI (0.12%, p = 0.36) compared to controls. With respect 
to a history of seizures, no differences between these groups 
were apparent (pre-symptomatic AD: 1.8%, p = 0.71; AD 
impaired-not-MCI: 2.33%, p = 0.50; AD MCI: 1.28%, 
p = 0.67).
Discussion
In our analyses of the NACC database with nearly twenty-
one thousand individuals, standardized assessment of sei-
zures with information obtained from study participants 
and their mandatory co-participants, from medical records 
and from observation, as well as AD diagnosis according to 
established criteria [13, 14], we revealed for the first time 
the exceptionally high recurrence risk for seizures of over 
70% within about seven and half months in AD dementia 
patients. Based on this finding, it can be discussed that one 
unprovoked or reflex seizure should lead to the diagnosis 
of epilepsy in AD dementia according to the current guide-
lines of the International League Against Epilepsy (ILAE), 
which postulates a recurrence risk of at least 60% in ten 
years after a first unprovoked or reflex seizure for the diag-
nosis of epilepsy [17]. If AD dementia-associated epilepsy 
is diagnosed, the high recurrence risk as shown in our study 
should implicate the consideration of an antiepileptic treat-
ment. It should also be noted, that the recurrence risk may be 
underestimated in this study as active seizures may prevent 
AD patients from further study participation. Additionally, 
a part of the evaluated individuals may already receive an 
antiepileptic medication mitigating seizure prevalence at 
follow-up. Further arguments for the consideration of an 
antiepileptic drug treatment are that AD-associated seizures 
are responsive to a low dose monotherapy in many cases 
[17–21], and are associated with poor cognition and function 
as shown in this study as well as can accelerate cognitive 
decline [22, 23].
Of particular interest is the question if seizure recur-
rence risk is higher in AD than in older individuals with 
epilepsy without an overt neurodegenerative condition. In 
a recent study a recurrence risk within one year after a first 
unprovoked seizure of 53% in older individuals (mean age: 
73 years; AD dementia patients with seizures in this study 
for comparison: 71 years) regardless of seizure etiology 
was reported [24]. These 53% within one year compare to 
the > 70% within seven and a half months in AD-associated 
epilepsy as found in this study. An interpretation could be 
that AD-associated epilepsy features a higher recurrence risk 
than seizures in older individuals with mixed seizure etiolo-
gies. However, it has to be considered that diagnosing of 
seizures in AD faces particular challenges. On the one hand, 
seizures can go unrecognized in AD, i.e., due to memory 
problems of the respective patients. On the other hand, sei-
zures can be wrongly suspected on the basis of cognitive 
fluctuations and other non-epileptic symptoms.
We found an association of seizures with worse cogni-
tive and functional performance in AD dementia patients. 
This association may suggest that seizures promote cogni-
tive decline in AD. Another interpretation could be that AD 
patients who are more severely affected by cognitive dete-
rioration are at an increased risk of seizures. However, we 
showed that AD patients with seizures performed worse in 
cognitive and functional tasks compared to patients without 
seizures after accounting for disease duration as a poten-
tial surrogate parameter of disease severity. This may also 
Fig. 3  Association of prevalence of active seizures and disease dura-
tion in patients with Alzheimer’s disease dementia. Logistic regres-
sion with disease duration squared transformed and standardized 
as explanatory variable (Quadratic equation: logit{P(“having a 
seizure”|disease duration = d)} = −  3.56 + 0.44 × (d−md/sdd)2 with 
md = 72.7 and  sdd = 35.0 being the mean and the standard deviation 
over all disease durations). The effect of disease duration on sei-
zure prevalence was highly significant in patients with AD dementia 
(OR = 1.55, 95% CI = 1.39–1.73, p < 0.001)
Fig. 4  Prevalence of seizures in the various stages of Alzheimer’s dis-
ease and in controls. Prevalence of active seizures and a history of 
seizures were higher in AD dementia patients compared to controls. 
No differences in seizure prevalence in pre-dementia stages of AD 
compared to controls were found. AD Alzheimer’s disease, MCI mild 
cognitive impairment. *p < 0.001
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implicate the consideration of an antiepileptic treatment on 
an individual basis.
It is still unclear, if seizures are associated with an earlier 
age of AD onset [5]. The inverse association between preva-
lence of seizures and age of symptom onset of AD observed 
in this study may shed light on this lack of clarity. Our find-
ing allows two interpretations. First, seizures may foster AD 
pathology [25, 26] and precipitate cognitive symptoms [22, 
23]. Second, individuals with AD at a younger age are more 
susceptible to seizures, i.e., feature a lower seizure threshold, 
compared to older individuals.
With respect to an association between AD severity and 
seizure risk, findings are at variance in the literature. Some 
studies suggest such an association [27, 28], whereas others 
showed an increased risk for seizures in AD that was inde-
pendent from the disease stage [29, 30]. Adding to clarifica-
tion, we found a strong association between duration of AD, 
i.e., the time from the onset of the first cognitive symptom, 
and the frequency of active seizures.
We confirmed and refined the increased risk for seizures 
in patients with AD dementia that was suggested previously 
[4, 5, 31] in a large prospectively assessed dataset with AD 
diagnosis according to established criteria [13, 14] and 
standardized seizure assessment. The odds ratio of 4.34 for 
active seizures found fits well with the estimated two- to six-
fold increase in seizure risk in AD patients of a recent review 
article [5]. Of note, the risk derived from the current analy-
sis is more likely underestimated as seizures in the NACC-
UDS are assessed by only a single item [10]. Our results 
do not indicate that the predementia stage of AD carries an 
increased risk for seizures. This is particularly remarkable 
as we stipulated the diagnosis of AD dementia at a subse-
quent visit for the classification of the predementia stages to 
improve diagnostic accuracy. This finding is at odds with an 
increased seizure prevalence in the pre-symptomatic phase 
of autosomal dominant Alzheimer’s disease (ADAD) [7]. 
A potential explanation could be that pathology in sporadic 
AD has to reach a higher threshold to increase seizure risk 
than in ADAD due to a higher susceptibility of the younger 
ADAD population for seizures. Another reason could be that 
the early pre-symptomatic seizures in ADAD are driven by 
mutation specific effects. However, also a reduced probing 
of raters in non-demented individuals in this study could 
be critical.
Both amyloid β and tau, the neuropathological hallmarks of 
AD, have been linked to seizure generation [5]. Mouse stud-
ies suggested a direct excitatory effect of amyloid β on brain 
networks [32]. Our study showed an increased risk for seizures 
not before the dementia state of AD and a growing risk with 
disease duration. As tau pathology seems to be closely linked 
to the occurrence of cognitive symptoms [33], our findings 
could be in line with an obligatory presence of both amyloid 
β and tau for seizure development and further could be in 
accordance with a proposed synergistic effect of these patholo-
gies on the generation of seizures [34].
Strengths of our study are the large size of the cohort with 
over twenty thousand individuals in this investigation, yearly 
prospective data collection over more than a decade, and the 
standardized assessment with the well-validated UDS [10, 11]. 
Limitations are that antiepileptic medication which can have 
an effect on seizure recurrence is not analyzed, semiology of 
seizures was not assessed, and with respect to the analysis of 
seizure recurrence risk the dropout rate of approximately 56%. 
It can be discussed that the dropout rate may in part be caused 
by ongoing seizures restraining patients from further study 
participation. Further, the diagnosis of seizures in older indi-
viduals is challenging and their outcomes rely on self-report. 
Stroke history is not evaluated and therefore potential effects 
of strokes that did not prevent the affected participant from 
further study participation on seizure occurrence in our study 
population cannot be estimated precisely. As neuroimaging 
is not assessed, cortical lesions such as microhemorrhages or 
subclinical infarcts that could be contributing to the develop-
ment of seizures cannot be ruled out. Additionally, there could 
be individuals with ADAD in the population of this study who 
are known to be at risk for seizures [36]. As the frequency of 
ADAD causing mutations in patients with AD is about or less 
than one percent [35] and the mean age of individuals with AD 
in this study (symptomatic AD: ~ 75 years, presymptomatic 
AD: ~ 80 years) corroborates the assumption that there is no 
substantial portion of individuals with ADAD in the study 
population, we did not perform analyses in detail regarding 
this subgroup that is expected to be very small.
In summary, in this study we reveal an exceptionally high 
recurrence risk of seizures in patients with AD dementia that 
should be considered in treatment of AD-associated seizures. 
Our results may answer open questions regarding an asso-
ciation of seizures with lower cognitive performance and a 
younger age of onset. A strong association between disease 
duration and seizure risk is demonstrated. Furthermore, the 
evidence for an increased seizure risk in AD dementia is con-
firmed and refined in a large cohort with consistently, prospec-
tively assessed data.
Our findings corroborate the relevance and impact of sei-
zures in clinical care of AD dementia, inform individual treat-
ment decisions, and emphasize the necessity of prospective, 
double-blind, randomized, controlled, parallel-group antiepi-
leptic treatment trials in AD.
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